No Data
Shareholders in Yifan Pharmaceutical (SZSE:002019) Have Lost 41%, as Stock Drops 4.3% This Past Week
Yifan Pharmaceutical (002019.SZ): Ryzneuta's marketing authorization application has been approved by ANVISA.
Gelonghui, December 20th丨Yifan Pharmaceutical (002019.SZ) announced that the company recently learned through the "Official Gazette of the Federal Government of Brazil (Diário Oficial da União)" that its product, Abegrin α injection (internal development code: F-627, referred to as "Ryzneuta"), has received approval for marketing authorization, permitting its sale in Brazil.
Yifan Pharmaceutical Gets Registration Approval of Ointment in Singapore
Yifan Pharmaceutical (002019.SZ): The anti-itch ointment has received registration approval in Singapore.
On December 16, Gelonghui reported that Yifan Pharmaceutical (002019.SZ) announced that its wholly-owned subsidiary SciGen Pte. Ltd. recently received the registration approval for Chinese Patent Medicine issued by the Health Sciences Authority (HSA) of Singapore, allowing the company to exclusively market its anti-itch ointment in Singapore. The anti-itch ointment's main functions are to clear heat and eliminate dampness, dispel wind, and relieve itching. It is used as an adjunct treatment for acute and subacute eczema cases associated with damp-heat or damp obstruction.
Yifan Pharmaceutical (002019.SZ): A wholly-owned subsidiary participates in the national pharmaceutical centralized procurement for some products intended for selection.
Gelonghui reported on December 13 that Yifan Pharmaceutical (002019.SZ) announced that on December 12, 2024, its wholly-owned subsidiary Hefei Yifan Biopharmaceutical Co., Ltd. and Liaoning Yifan Pharmaceutical Co., Ltd. participated in the bidding for the 10th batch of national centralized pharmaceutical procurement organized by the National Organization for Drug Centralized Procurement Office (hereinafter referred to as "Centralized Procurement Office"). Some of the company's products are expected to be selected in this centralized procurement. The products expected to be selected include Lacosamide injection, Levobetaxolol hydrochloride injection, Nimodipine injection, and Pyridostigmine methylsulfate injection. The expected selection prices are 7.93 yuan, 0.
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Prospects Need A Boost To Lift Shares
Yifan Pharmaceutical Co., Ltd.'s (SZSE:002019) Share Price Not Quite Adding Up